R&D channel feed – Endpoints News

R&D channel feed

Athenex discloses patient death, clinical hold on CAR-NKT trial as it seeks strategic alternatives

3 years ago

Karuna’s schizophrenia drug clears another PhIII as biotech seeks 2024 launch

3 years ago

What kind of PhIIb data is worth $4B cash? Takeda’s Andy Plump has some thoughts on that

3 years ago

Gossamer stops enrollment on BTK inhibitor program, goes all in on PAH drug

3 years ago

Pfizer, Astellas tout positive PhIII data to potentially expand Xtandi label

3 years ago

Merck's Keytruda plus TIGIT combo proves less effective than chemo in open-label lung cancer study

3 years ago

'Very real' headwinds: With leaner staff, cancer vaccine maker searches for help

3 years ago

In ‘surprise’ move, BioXcel files for cancer subsidiary to go public

3 years ago

Esperion stock halved after Daiichi discord over $440M heart pill milestones

3 years ago

UK R&D credit increase, faster drug approvals promised in budget speech

3 years ago

FDA partially lifts dosing hold on Stoke Therapeutics' pediatric Dravet syndrome study

3 years ago

German cannabis medicine manufacturer lands $17M+ in funding

3 years ago

Dermavant says Vtama topical cream works in PhIII eczema trial

3 years ago

Sigilon focuses on type 1 diabetes, reduces spend on MPS-1 after letting CMO go (corrected)

3 years ago

Bellicum halts trials after serious adverse event, looks for 'strategic alternatives'

3 years ago

Further shuffling at Leo Pharma as dermatology drugmaker splits R&D

3 years ago

Servier says its next IDH inhibitor has passed PhIII, but no regulatory timeline yet

3 years ago

Synaffix expands ADC deal from 2022 with MacroGenics

3 years ago

Bristol Myers passes on two Exscientia oncology candidates, but biotech to move them into clinic next year

3 years ago

Exercise in a pill? That's the focus of Cambrian's new pipeline company

3 years ago

Novo-backed startup touts a PhII win for atrial fibrillation program

3 years ago

Sun Pharma, Taro Pharmaceutical reach $75M settlement agreement in alleged price fixing scheme

3 years ago

Calliditas plans to file for full approval for rare kidney disease drug following PhIII data

3 years ago

Vertex heads to the clinic with a next-gen stem cell candidate for type 1 diabetes

3 years ago

First page Previous page 95 96 979899 100 101 Next page Last page